Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives
Open accessThe DOI matches its Crossref record; 209 of the 216 references it cites were found in a registry or an index.
Abstract
Stress-induced hyperglycaemia (SIH) at hospital admission for acute coronary syndrome is associated with poor outcome, especially in patients without known diabetes. Nevertheless, insulin treatment in these subjects was not correlated with the reduction of mortality. This is likely due to the fact that SIH in the context of an acute coronary syndrome, compared to that in known diabetes, represents an epiphenomenon of other pathological conditions, such as adrenergic and renin-angiotensin system over-activity, hyperglucagonaemia, increase of circulating free fatty acids and pancreatic beta-cell dysfunction, which are not completely reversed by insulin therapy and so worsen the prognosis. Thus, SIH may be considered not only as a biomarker of organ damage, but also as an indicator of a more complex therapeutic strategy in these subjects. The aim of this review is to analyse the molecular mechanisms by which SIH may favour a worse prognosis in non-diabetic patients with acute coronary syndrome and identify new therapeutic strategies, in addition to insulin therapy, for a more appropriate treatment and improved outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stress hyperglycaemia without diabetes is associated with adverse in-hospital outcomes, and should be suspected in those with raised glucose levels during admission and normal HbA1c.19”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Usami, M., Sakata, Y., Nakatani, D., Suna, S., Matsumoto, S., Hara, M., Kitamura, T., Ueda, Y., Iwakura, K., Sato, H., et al. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.08.012 · Cited by 18
Kramer, C. K., Zinman, B., Choi, H., & Retnakaran, R. R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1947 · Cited by 18 · cited 1×
“However, it has been postulated that administration of supraphysiological insulin levels to suppress glucagon secretion will probably not be sufficient to reach normal glycaemic values in hyperglucagonaemic patients with SIH [26].”
BackgroundPiloting a Novel Algorithm for Glucose Control in the Coronary Care Unit
Nerenberg, K. A., Goyal, A., Xavier, D., Sigamani, A., Ng, J., Mehta, S. R., Díaz, R., Kosiborod, M., Yusuf, S., Gerstein, H. C., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0706 · Cited by 17 · cited 1×
“Conversely, others did not evidence a significant statistical difference in achieved target glycaemic values, as well as in 90-day mortality or extension of myocardial injury between two therapeutic strategies [91,92].”
BackgroundSeverity of Coronary Atherosclerosis and Risk of Diabetes Mellitus
Colaiori, I., Izzo, R., Barbato, E., Franco, D., Gioia, G. D., Rapacciuolo, A., Bartúnek, J., Mancusi, C., Losi, M. A., Strisciuglio, T., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071069 · Cited by 16
Self-citationChaudhuri, A., Janicke, D. M., Wilson, M. F., Ghanim, H., Wilding, G. E., Aljada, A., & Dandona, P. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.07.014 · Cited by 15 · cited 2×
“Such FFA levels are reached in the early hours of ACS [75,76].”
BackgroundThe gut hormone GLP-2 predicts cardiovascular risk in patients with acute myocardial infarction
Kahles, F., Mertens, R. W., Rückbeil, M. V., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., Marx, N., et al. (2020) · European Heart Journal · doi:10.1093/ehjci/ehaa946.1592 · Cited by 9
NICE recommendations for the management of hyperglycaemia in acute coronary syndrome
Corbett, S. J. (2012) · Heart · doi:10.1136/heartjnl-2012-302421 · Cited by 8
[The role of glucagon in hyperglycemia. A review (author's transl)].
LUYCKX, A. S. (1975) · PubMed · Cited by 7
Buturlin, K., Minha, S., Rozenbaum, Z., Neuman, Y., Shlezinger, M., Goldenberg, I., Mosseri, M., & Pereg, D. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616641900 · Cited by 6
Research works printed but not linked: 1
- Diaz, 1998, Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group, Circulation, 98, 2227
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Caturano, A., Galiero, R., Pafundi, P. C., Cesaro, A., Vetrano, E., Palmiero, G., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108959 · Cited by 73
Cui, K., Fu, R., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Wang, Z., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3562 · Cited by 68
“In addition, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporters two inhibitors may significantly reduce the glucose levels and ischaemic cardiovascular events.(34,36)”
BackgroundLi, X., Yang, X., Dong, B.-B., & Liu, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02577-z · Cited by 63
Lin, Z., Liang, X., Zhang, Y., Dai, Y., Zeng, L., Chen, W., Kong, S., He, P., Duan, C., & Liu, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01799-3 · Cited by 56
Metadata
- Authors
- Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C.
- Affiliations
- Ospedale Antonio Cardarelli (IT)
- University of Naples Federico II (IT)
- MultiMedica (IT)
- Corresponding author
- Morisco, Carmine
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-14
- Volume
- 22
- Issue
- 2
- Pages
- 775
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7828822
- OpenAlex
- W3121056265
- Cited by
- 61
- References
- 216
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 14 · 2023: 10 · 2022: 7 · 2021: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- stress hyperglycemia, acute coronary syndrome, non-diabetic patients, insulin therapy, prognosis, adrenergic system, renin-angiotensin system, hyperglucagonaemia, free fatty acids, beta-cell dysfunction, molecular mechanisms, treatment options
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Animals, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Stress, Psychological, Acute Coronary Syndrome, Dipeptidyl-Peptidase IV Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.